Aphria Inc (NYSE:APHA) – Equities research analysts at Seaport Global Securities cut their Q1 2020 earnings estimates for shares of Aphria in a note issued to investors on Wednesday, March 27th, according to Zacks Investment Research. Seaport Global Securities analyst B. Hundley now expects that the company will earn ($0.05) per share for the quarter, down from their previous forecast of ($0.04). Seaport Global Securities currently has a “Buy” rating and a $18.00 target price on the stock. Seaport Global Securities also issued estimates for Aphria’s Q2 2020 earnings at $0.00 EPS and FY2020 earnings at $0.09 EPS.
Several other analysts have also weighed in on the company. Zacks Investment Research lowered Aphria from a “hold” rating to a “sell” rating in a report on Friday. Clarus Securities started coverage on Aphria in a report on Tuesday, April 16th. They set a “buy” rating and a $22.75 price target on the stock. ValuEngine lowered Aphria from a “buy” rating to a “hold” rating in a report on Monday, April 15th. Cormark set a $15.00 price target on Aphria and gave the company a “buy” rating in a report on Saturday, February 2nd. Finally, CIBC started coverage on Aphria in a report on Friday, January 18th. They set a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $15.69.
A number of hedge funds have recently added to or reduced their stakes in the business. Pennsylvania Trust Co purchased a new stake in Aphria in the first quarter worth $18,601,000. Virtu Financial LLC purchased a new stake in Aphria in the first quarter worth $669,000. Truvestments Capital LLC purchased a new stake in Aphria in the first quarter worth $61,000. Deutsche Bank AG purchased a new stake in Aphria in the fourth quarter worth $960,000. Finally, Liberty Wealth Management LLC bought a new position in shares of Aphria during the 4th quarter worth $35,000. Institutional investors and hedge funds own 10.39% of the company’s stock.
Aphria Company Profile
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Further Reading: SEC Filing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.